Abstract Background: Green tea extract (GTE) may be involved in a favourable postprandial response to high-carbohydrate meals. The catechol-O-methyltransferase (COMT) genotype may modify these effects. We examined the acute effects of GTE supplementation on the post-prandial response to a high-carbohydrate meal by assessing appetite-associated hormones and glucose homeostasis marker concentrations in women who consumed 843 mg of (À)-epigallocatechin-3-gallate (EGCG) or placebo capsules for 11-12 months. Methods: Sixty Caucasian post-menopausal women (body mass index ≥ 25.0 kg m -2 ) were included in a randomised, double-blind feeding
Introduction
Being overweight and obesity are major public health concerns, with worldwide obesity rates having doubled since 1980 (1) . Obesity is associated with several serious health conditions, including cardiovascular disease, diabetes and select cancers, such as post-menopausal breast cancer (2) (3) (4) . Studies have suggested that green tea and its high content of polyphenolic catechins may reduce risk for these diseases in part via beneficial effects on body weight because green tea consumption has been shown to modestly reduce body weight and adiposity in many randomised controlled trials (RCTs) and one meta-analysis (5) (6) (7) (8) . Among the catechins present in green tea, the four most prominent types are epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG) and (À)-epigallocatechin-3-gallate (EGCG). EGCG has been the most widely studied and is considered to be the most bioactive catechin (9) . However, these results have not been consistent across varying study designs and populations because several RCTs and one Cochrane review have shown no clinically meaningful weight loss or weight maintenance effects with green tea supplementation (7, 10, 11) . Numerous mechanisms have been proposed for the antiobesity effects of green tea catechins (GTC), including increases in b-oxidation and thermogenesis (12) (13) (14) , as well as reductions in adipocyte differentiation and proliferation, lipogenesis and nutrient absorption (9, (15) (16) (17) , as demonstrated in in vitro, animal and human experiments. Another mechanism by which GTC may reduce body weight or promote weight maintenance is by modifying several hormones associated with energy balance, the post-prandial glycaemic response and satiety. In humans, the gut-derived hormone ghrelin, as well as adipose-derived adiponectin and leptin, have been shown to be involved in appetite cues and satiety after the ingestion of a meal, respectively. Insulin has also been associated with energy balance (18) , and several RCTs have demonstrated increased insulin sensitivity with the consumption of GTC (19) (20) (21) . However, few human studies examining the immediate post-prandial effects of GTC on these hormones have been conducted (22, 23) . To date, the results are inconclusive, with one study finding no differences in the area under the curve (AUC) for glucose and insulin after meal consumption, although higher satiety was reported among participants (22) , whereas another single-arm study did not provide a control group to enable a comparison of the results (23) . The proposed beneficial effects of GTC on body weight and adiposity may be further modulated by the catechol-O-methyltransferase (COMT) enzyme, which is one of the main enzymes responsible for catechin degradation as well as metabolism of catecholamines, including norepinephrine. The gene encoding COMT is polymorphic and its alleles correspond to different activity levels of the enzyme: A/A = homozygous low-activity; A/G = heterozygous intermediate-activity; and G/G = homozygous highactivity. An amino acid change from valine to methionine at codon 108/158 reduces the thermostability of the enzyme and lowers its enzymatic activity by 66-75% (24, 25) . These differences in activity are considered to affect individual variation in metabolism of GTC, thus potentially influencing the biological effects of green tea consumption on weight loss and weight control. In addition, GTC have been shown to inhibit the action of COMT in vitro, which is significant given that COMT is also responsible for the metabolism of norepinephrine, a potent sympathetic nervous system stimulant. Reduced activity of COMT may prolong the effects of norepinephrine with respect to increasing thermogenesis and satiety (26, 27) . The primary aim of the present study was to determine the effect of a decaffeinated green tea extract (GTE) containing 1315 mg total catechins day -1 (843 mg as EGCG)
on post-prandial concentrations of appetite-related hormones and blood glucose in overweight and obese postmenopausal women. The secondary aims were to assess the effects of GTE on satiety and to evaluate the modification of these effects by COMT genotype. We hypothesised that GTE supplementation would cause favourable changes in hormone concentrations and increase postprandial satiety, and that women with the low-activity genotype (A/A) would have a more favourable response to GTE consumption compared to those with the intermediate-(A/G) or high-activity (G/G) COMT genotypes, as a result of greater exposure to GTC.
Materials and methods

Study design
This ancillary study was conducted in a subset of overweight and obese women who were enrolled in the Minnesota Green Tea Trial (MGTT), a phase II, randomised, double blind, placebo-controlled, intervention study that has been described in detail elsewhere (28) . In the parent study, healthy post-menopausal women at high-risk of breast cancer as a result of increased mammographic density were randomised by COMT genotype to consume either four decaffeinated (<16 mg caffeine day À1 ) GTE capsules containing a mean (SD) total of 1315 (116) mg GTC [843 (44) mg as EGCG] or placebo capsules daily for 12 months to determine the effects of GTE exposure on several breast cancer biomarkers, including mammographic density, reproductive hormones, oxidative stress and insulin-like growth factor axis proteins.
To evaluate the acute post-prandial effects of GTE consumption following a standardised meal, 60 subjects (10 from each treatment/genotype group) were invited to participate during months 11 or 12 of the 12-month parent study. This research took place during a half-day clinic visit at the University of Minnesota's Delaware Clinical Research Unit. For the half-day visit, participants were instructed to adhere to their normal energy intake and to refrain from exercise and alcohol on the day before the test day. They arrived at the research unit after a 10-h fast. Baseline satiety questionnaires were completed and fasting blood was drawn for assessment of the energy-related hormones. Participants were then instructed to consume two GTE capsules and a standardised high-carbohydrate breakfast meal (consisting of a bagel with cream cheese, orange juice and low-fat, fruit-flavored yogurt or 2% milk). Blood was drawn immediately post-meal and every 30 min over a period of 4 h for evaluation of change in energy-and obesity-related hormones. To minimise external influencers of satiety, each test meal session was conducted independently and the participant and test meal administrator were the only individuals in the room. Participants were allowed to bring in outside materials to read during their session, although instructions were not given to avoid food-related content. Satiety questionnaires were completed before the meal, immediately after the consumption of the meal, and every hour thereafter for a total of six questionnaires.
Participant recruitment and eligibility criteria
Participant eligibility, screening, recruitment and randomisation followed the same protocol as the parent study (28) . Primary inclusion criteria included healthy, nonsmoking post-menopausal women aged 50-70 years classified as having 'heterogeneously dense' or 'extremely dense' breast tissue by a trained radiologist after a routine screening mammogram. Of 1075 women randomised into the parent study, 230 women classified as overweight (body mass index = 25.0-29.9 kg m -2 ) or obese (body mass index = 30.0-40.0 kg m -2 ) at the screening clinic visit were invited to participate in this acute feeding study from 2012 to 2014. Of these, 149 participants responded to the invitation, 50 were excluded because of the need for equal numbers in each COMT genotype group. An additional 38 women did not participate for other reasons (Fig. 1) . Sixty-one participants were randomised into the study (GTE: n = 30; placebo: n = 31). One participant in the placebo group was excluded as a result of not consuming the intervention product with the breakfast meal, and so the final sample size was 30 participants per treatment group. 
Randomisation, blinding and participant consent
Randomisation of subjects was performed by the University of Minnesota Medical Center-Fairview's Investigational Drug Service pharmacy using a computergenerated permuted block randomisation scheme. Both participants and investigators were blinded to the treatment of subjects. Institutional Review Board approval was obtained at each clinical centre. All participants provided their additional written informed consent for this ancillary study. This trial was registered at clinicaltrials.gov as NCT00917735.
Determination of catechol-O-methyltransferase genotype
DNA was purified from buffy coats of peripheral blood samples using a PureGene Blood kit (Gentra Systems, Minneapolis, MN, USA). A TaqMan assay was developed for determining the COMT G/A polymorphism using a TaqMan polymerase chain reaction (PCR) Core Reagent kit (Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer's instructions. PCR amplification using approximately 10 ng of genomic DNA was performed in a thermal cycler (MWG Biotech, Inc., High Point, NC, USA) with an initial step of 95°C for 10 min followed by 50 cycles of 95°C for 25 s and 62°C for 1 min. The fluorescence profile of each well was measured in an ABI 7900HT Sequence Detection System (Applied Biosystems) and the results were analysed using Sequence Detection Software (Applied Biosystems). Experimental samples were compared with 12 controls to identify the three genotypes at each locus (G/G, G/A, and A/A).
Green tea extract composition
The present study used decaffeinated Green Tea Extract Catechin Complex (referred to as GTE in this publication) in capsule form, as provided by Corban Laboratories (Eniva Nutraceutics, Plymouth, MN, USA). Mean (SD) daily catechin content was 1315 (116) mg day
À1
[843 (44) mg as EGCG]. Placebo capsules were identical in appearance to GTE and contained 816 mg of maltodextrin, 808 mg of cellulose and 8 mg of magnesium stearate (flow agent). Participants were required to consume four capsules daily and were advised to ingest two capsules in the morning hours and two in the evening to maintain circulating catechin concentrations throughout each day, and to take the capsules with meals to reduce any potential gastrointestinal discomfort associated with consuming GTE in the fasted state. For this sub-study, participants were asked to consume the morning dose of GTE with the breakfast meal.
Demographics and data collection
All participants completed a health history questionnaire upon entry into the parent study that included comprehensive data of demographics, lifestyle factors (physical activity, smoking history and alcohol intake), as well as information about medical history, medication use (current and former) and full reproductive history.
Dietary intake
To evaluate dietary intake, participants were asked to record food intake on two assigned weekdays and one weekend day in the week prior to the half-day visit. Recording errors were minimised by providing the subjects detailed instructions on how to keep accurate diet records. Subjects were encouraged to measure foods eaten using measuring spoons and cups whenever possible. Diet records were then reviewed for accuracy and completeness during the clinic visit by a registered dietitian nutritionist and later analysed for nutrient content using the FOOD PROCESSOR DIET NUTRITION ANALYSIS AND FITNESS software, version 10.10 (ESHA Research, Salem, OR, USA). The average of the 3 days was used to represent typical food and nutrient intake.
Test meal composition
The 
Biological sample analysis
Plasma adiponectin, leptin and ghrelin were measured using radioimmunoassay kits manufactured by EMD Millipore (Billerica, MA, USA) [inter-assay % coefficient of variation (% CV): leptin = 9.8%, adiponectin = 8.6%, ghrelin = 6.2%; intra-assay % CV: leptin = 10.1%; adiponectin = 7.7%, ghrelin = 8.1%]. Serum insulin was measured using a simultaneous one-step immunoenzymatic, chemiluminescent assay (Access Ultrasensitive Insulin assay; Quest Diagnostics, Wood Dale, IL, USA, intra-assay % CV: 3-5.0%; inter-assay % CV = 3.9%). Serum glucose concentrations were measured using a hexokinase enzymatic reference method (Quest Diagnostics, monthly % CV = 1.4%).
Assessment of satiety
To test satiety, a set of nine visual analogue scale (VAS) ratings associated with the standardised high-carbohydrate test meal was used. Questionnaires were completed pre-meal, post-meal (time 0), and hourly thereafter and were administered after blood draws at these time points.
Participants were asked to answer each separate VAS question relating to hunger, fullness, desire to eat, prospective consumption, perceived satiety, contentedness, irritability, sleepiness and mental alertness in a continuous linear scale from 0 to 10 cm, where 0 represented 'not/none at all' and 10 represented 'extremely/very'. The VAS is considered to be a valid and reliable assessment tool for monitoring the effects of energy, palatability and macronutrient manipulations on subjective ratings in appetite studies (29, 30) .
Statistical analysis
Power calculations were unable to be performed for the half-day post-prandial sub-study because there were no data available on these outcomes at that time. We chose 60 participants as a feasible number that was comparable to similar studies examining energy-related hormones in response to a specific dietary component. We aimed to achieve equal numbers of participants with each COMT genotype in each treatment group and, although this reduced the power for between-genotype comparisons, it should be noted that these results were intended to be exploratory in nature. Demographic characteristics of participants at baseline were compared between treatments using a one-sample ttest for continuous variables. Natural logarithmic transformation was considered to normalise the distribution of these variables. Chi-squared and Fisher's exact tests were used to compare the distribution of categorical variables between treatments. Change in hormones (leptin, ghrelin, adiponectin and insulin) and blood glucose over time were evaluated using linear regression with repeated measurements. Hormones and blood glucose were transformed using natural logarithms to normalise their distribution. The model included time, treatment, COMT genotype and the two-and three-way interactions as explanatory variables. Interactions were excluded from the model if nonsignificant at P < 0.05, using backward elimination. When statistically significant differences were detected, a post hoc pairwise comparison across treatment and COMT genotype groups was performed. An unstructured working correlation matrix was fitted to model the correlation between time points within participants; this was chosen based on Akaike's information criterion. The AUC of the VAS at different time points before and after the meal was calculated for each participant and each VAS question using the trapezoid method. The AUC values of each question and participant were used as dependent variables in a linear mixed model to evaluate the effect of treatment on the AUC of each question. Baseline VAS (pre-meal) was used as a random effect in the model. Model assumptions were evaluated using residual plots and Cook's distance greater than 0.5 was used to evaluate possible influential outliers for both hormones and VAS measures. P ≤ 0.05 was considered statistically significant for all comparisons. All analyses were conducted using SAS, version 9.4 (SAS Institute, Inc., Cary NC, USA).
Results
Baseline characteristics
Participants randomised to GTE and placebo were similar with respect to baseline demographics and characteristics (Table 1) . Groups differed in the distribution of level of education, in that the GTE group had a greater number of participants who had obtained education beyond high school (P = 0.001). Mean intake of macro-and micronutrients as assessed by 3-day diet records did not differ by treatment group.
Post-prandial hormone and glucose response
Post-prandial concentrations of leptin, ghrelin and adiponectin are presented in Fig. 2 . Baseline fasting concentrations of all variables were similar between treatment groups. These hormone concentrations were not different between GTE and placebo at any time point, and COMT genotype did not modify these results.
There was a statistically significant interaction between treatment and COMT genotype for insulin and glucose that varied across time (Fig. 3) . Participants randomised to GTE with the high-activity form of the COMT enzyme (GTE-high COMT) had significantly higher insulin concentrations at time 0 (post-meal), 0.5 and 1.0 h post-meal compared to all COMT genotype groups randomised to placebo. Insulin concentrations remained significantly higher in the GTE-high COMT group 1.5, 2.0 and 2.5 h compared to the Placebo-low COMT group (P < 0.02). The GTE-high COMT group also had higher insulin concentrations at time 0, 0.5, 1.0, 1.5 and 2.0 h after the meal compared to the GTE-low COMT group (P ≤ 0.04). No differences between treatment groups and COMT genotypes existed 3.0, 3.5 or 4.0 h after the meal. With respect to glucose, the GTE-high COMT group had significantly higher glucose concentrations at time 0 compared to Placebo-high COMT (P = 0.05) and the GTE-low COMT group (P = 0.004). The GTE-low COMT group had higher serum glucose 3.5 h post-meal compared to the GTE-high COMT and Placebo-low COMT groups (P = 0.01 and P = 0.05, respectively). Insulin AUC comparisons within genotypes between treatment groups are shown in Table 2 . The insulin AUC for GTE-high COMT was significantly higher compared to Placebo-high COMT at all time points, although the mean AUC comparison failed to reach significance (P = 0.06). Mean insulin AUCs between intermediateand low-COMT groups did not differ at any time point, and glucose AUCs did not differ within any COMT genotype between treatment groups (data not shown).
Appetite sensations
AUC measurements of satiety-related variables did not show any significant difference between treatments at baseline or over the 4-h time period between GTE and placebo groups (See Supporting information, Table S1 ).
COMT genotype did not modify these results.
Discussion
The results of the present study indicate that GTE supplementation does not alter the acute post-prandial response of leptin, ghrelin or adiponectin after the consumption of a high-carbohydrate meal, and that COMT genotype does not modify this relationship. However, GTE supplementation and COMT genotype may be involved in the postmeal glycaemic response because significant interactions were observed between COMT genotype and glucose and insulin concentrations over the 4-h test period. No effect of GTE or COMT genotype was seen on measures of post-prandial satiety. To our knowledge, this is the first study to examine the effect of GTE supplementation on acute post-prandial concentrations of the appetite-associated hormones leptin, ghrelin and adiponectin. We did not find significant differences between treatment groups in these hormones prior to the meal or at any time point thereafter, indicating that GTE did not modify fasting concentrations of ghrelin, leptin and adiponectin in these participants. This is consistent with our previous work, which demonstrated that GTE did not modify concentrations of these hormones over the 12-month intervention period of the MGTT in a larger sample of overweight and obese study participants (11) . We did observe a somewhat unexpected leptin response, in which plasma leptin concentrations decreased moderately from pre-meal to 1.5 h in both groups before increasing to the end of the 4-h period. Yet, these results correlate with other studies that have examined leptin concentrations in overweight and obese women after a high-carbohydrate meal (31, 32) , affirming that obesity is associated with an impaired post-prandial leptin response. When correlated with the AUC analysis of satiety-related endpoints, satiety and prospective food intake were not differentially influenced by the effect of GTE on energy-related hormones. Taken together, the results of these studies indicate that any effect of GTE supplementation is not mediated through alteration of leptin, ghrelin or adiponectin concentrations.
We observed a significant interaction between GTE, COMT genotype and time, in which participants randomised to GTE with the high-activity (G/G) form of the COMT enzyme demonstrated increased post-prandial insulin concentrations compared to the Placebo-high COMT and GTE-low (A/A) COMT groups, despite similar glucose profiles at most time points. The significance of an increased insulin response to a high-carbohydrate meal in participants with the G/G genotype taking GTE is unclear, although it could be indicative of the need to secrete additional insulin to manage blood glucose concentrations over time compared to individuals with other forms of the COMT genotype and those not taking GTE; yet, the sample size of this group was small, making it difficult to draw definitive conclusions. Our results are in agreement with those of another study (23) that reported finding greater post-prandial insulin concentrations after the consumption of GTE (836 mg catechins) in individuals with the G/G genotype compared to those with the G/A or A/A COMT genotypes. Similarly, Kring, et al. (33) determined that there was an 11.6% increased frequency of the G/G COMT genotype in individuals with impaired glucose tolerance or type 2 diabetes. These studies and our results appear to suggest that the high-activity form of the COMT enzyme is associated with increased risk for glycaemia-related health conditions, and that GTE consumption may potentiate an exaggerated insulin response after a meal. These results coincide with our previous findings in a larger sample of post-menopausal overweight and obese women (n = 237) (11) , in which participants with the G/G form of COMT showed significantly higher insulin concentrations at month 12 compared to those with the A/A genotype irrespective of treatment group (GTE and placebo groups combined); yet, among participants with baseline fasting insulin ≥10 lIU mL
À1
, reductions in fasting insulin concentrations were seen in the GTE group over 12 months compared to both the placebo group and all participants with baseline insulin < 10 lIU mL À1 . It is plausible that GTE consumption may elicit a higher immediate post-prandial insulin response, particularly in those with the G/G COMT genotype, at the same time acting to reduce fasting insulin concentrations over time. Additional research is needed to determine the specific mechanisms of the COMT enzyme on insulin concentrations after the administration of GTE and how this may affect the shortand long-term glycaemic response. Early animal studies demonstrated reduced food intake with administration of green tea catechins (9, 34) , indicating that green tea might increase satiety. However, this effect has not been confirmed in human subjects. One study found that the inclusion of 167 mg of green tea catechins and 100 mg of caffeine in a beverage containing 10 g of soluble fibre created lower hunger and higher fullness ratings and was associated with the lowest energy intake in the next meal compared to fibre-only (46 mg caffeine), isocaloric control beverage (no caffeine) and no beverage conditions (35) . By contrast, Diepvens, et al. (26) showed that women randomised to receive green tea (1125 mg catechins + 225 mg caffeine day À1 ) for almost 3 months with a low-energy diet became hungrier over time and showed increased prospective food consumption compared to placebo. It was suggested that this could be a result of down-regulation of the leptin response through stimulation of the sympathetic nervous system by green tea because leptin is known to reduce appetite. However, leptin concentrations were not measured in their study, and so this conclusion could not be An asterisk indicates a significant difference (P < 0.05) between the GTE-high and GTE-low groups. A "#" indicates a significant difference between GTE-high and PLA-low groups and " †" indicates a significant difference between GTE-high and all Placebo-COMT genotype groups. " ‡" indicates a significant difference between GTE-high and PLA-high groups. *P < 0.05, GTE-high (n = 10) versus GTE-low COMT (n = 10); #P < 0.05, GTE-high (n = 10) versus PLA-low COMT (n = 10); †P < 0.05, GTE-high (n = 10) versus all PLA COMT (n = 10); ‡P < 0.05, GTE-high (n = 10) and PLA-high COMT (n = 10). COMT, catechol-O-methyltransferase; GTE, green tea extract; PLA, placebo.
confirmed. Several other RCTs examining the effect of GTC on acute measures of satiety (36, 37) or long-term changes in energy intake (5, 11, 38) have shown null results, including the present study, in which we did not observe differences between treatment groups in any of the nine questions related to hunger, satiation and prospective food intake in the 4 h following a high-carbohydrate breakfast meal.
The results of this research contribute depth not only to the growing body of research on the effects of GTC on insulin sensitivity, but also to the association between COMT genotype and risk for glycaemia-related health conditions. Our results also indicate that GTE does not induce appetite inhibition or satiety, thus weakening the argument for these effects as mechanisms behind the association of green tea with reductions in body weight and adiposity. However, our research has several limitations. We conducted this analysis after just one meal and were unable to compare each participant's response to that of a reference meal. There was no measure of hedonic liking of the meal, which may have influenced satiety and prospective food intake. Standardisation of the diets of participants 24 h prior to the breakfast meal could have increased the similarity of the glycaemic response. Participants were not required to follow a low-catechin diet for the duration of the study, and so the ingestion of catechins from foods and beverages other than green tea likely contributed to total catechin intake. However, green tea consumption was restricted throughout the duration of the study, and the amount of GTC given in the intervention was far greater than could be ingested in a typical daily diet. Therefore, any risk of confounding was minimal. Lastly, because this was a small ancillary study with only 10 participants in each treatment/genotype group, we may have been underpowered to detect significant results and cannot rule out the possibility of type 2 error. Despite these limitations, these results indicate that supplementation of 1315 mg GTE per day for 12 months did not influence pre-or post-prandial concentrations of appetite-associated hormones or measures of satiety after a high-carbohydrate breakfast meal in overweight or obese post-menopausal women. Yet, GTE and COMT genotype may have specific influences on post-meal insulin and glucose concentrations, and these findings warrant additional research in larger study populations aiming to determine the specific impact of GTE on the post-prandial glycaemic response.
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